Prime Medicine Confirms Emerging Growth Company Status

Ticker: PRME · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1894562

Prime Medicine, Inc. 8-K Filing Summary
FieldDetail
CompanyPrime Medicine, Inc. (PRME)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, emerging-growth-company

TL;DR

**Prime Medicine is an emerging growth company, meaning less SEC red tape for now.**

AI Summary

Prime Medicine, Inc. filed an 8-K on January 8, 2024, to disclose that it is an "emerging growth company" as defined by the SEC. This status allows the company to take advantage of certain reduced reporting requirements, which can save them money and resources. For investors, this means less frequent and detailed disclosures compared to larger, more established companies, which could impact the transparency of their investment.

Why It Matters

This status allows Prime Medicine to operate with fewer regulatory burdens, potentially accelerating its growth but also providing less immediate transparency to investors.

Risk Assessment

Risk Level: low — The filing itself is a routine disclosure of company status and does not introduce new financial or operational risks.

Analyst Insight

Investors should be aware that Prime Medicine's emerging growth company status means it may provide less frequent or detailed financial disclosures than larger companies, requiring them to rely more on other sources for information.

Key Players & Entities

  • Prime Medicine, Inc. (company) — the registrant filing the 8-K
  • January 8, 2024 (date) — date of earliest event reported and filing date
  • Delaware (company) — state of incorporation for Prime Medicine, Inc.
  • 001-41536 (company) — Commission File Number for Prime Medicine, Inc.
  • PRME (company) — trading symbol for Prime Medicine, Inc. common stock
  • The Nasdaq Global Market (company) — exchange where Prime Medicine, Inc. common stock is registered

FAQ

What is the purpose of this 8-K filing by Prime Medicine, Inc.?

The purpose of this 8-K filing is to report that Prime Medicine, Inc. is an "emerging growth company" as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934, as indicated by the checked box in the filing.

What is Prime Medicine, Inc.'s trading symbol and where is its common stock registered?

Prime Medicine, Inc.'s common stock trades under the symbol PRME and is registered on The Nasdaq Global Market, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.

What is the earliest event reported date in this 8-K filing?

The earliest event reported date in this 8-K filing is January 8, 2024, as specified under 'Date of Report (Date of earliest event reported)'.

What is the business address of Prime Medicine, Inc.?

The business address of Prime Medicine, Inc. is 21 Erie Street, Cambridge, MA 02139, with a telephone number of (617) 564-0013, as listed in the filing's header information.

Under which SEC acts is Prime Medicine, Inc. indicating its emerging growth company status?

Prime Medicine, Inc. is indicating its emerging growth company status as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, as per the checkbox in the filing.

Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-01-08 08:01:06

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Prime Medicine, Inc. (the "Company") will be conducting meetings with participants attending the 42 nd Annual J.P. Morgan Healthcare Conference (the "Conference") during the week of January 8, 2024. A copy of the slides to be presented by the Company at the Conference is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Presentation at 42 nd Annual J.P. Morgan Healthcare Conference, dated January 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 Prime Medicine, Inc. By: /s/ Keith Gottesdiener Name: Keith Gottesdiener, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.